| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine-Related Disorders | 20 | 2017 | 461 | 2.360 |
Why?
|
| Pueraria | 7 | 2015 | 13 | 2.330 |
Why?
|
| Cocaine | 39 | 2017 | 958 | 2.300 |
Why?
|
| Hallucinogens | 6 | 2023 | 197 | 2.150 |
Why?
|
| Cues | 11 | 2023 | 875 | 1.860 |
Why?
|
| Cannabis | 6 | 2023 | 441 | 1.780 |
Why?
|
| Substance Withdrawal Syndrome | 14 | 2022 | 625 | 1.630 |
Why?
|
| Ethanol | 29 | 2012 | 1324 | 1.620 |
Why?
|
| Tobacco Use Disorder | 7 | 2019 | 703 | 1.620 |
Why?
|
| Alcoholism | 18 | 2013 | 1973 | 1.520 |
Why?
|
| Marijuana Smoking | 10 | 2013 | 258 | 1.440 |
Why?
|
| Gyrus Cinguli | 9 | 2023 | 1115 | 1.340 |
Why?
|
| Phytotherapy | 4 | 2015 | 296 | 1.280 |
Why?
|
| Cytidine Diphosphate Choline | 5 | 2011 | 29 | 1.190 |
Why?
|
| Hypnotics and Sedatives | 6 | 2014 | 1179 | 1.150 |
Why?
|
| Nicotine | 13 | 2023 | 680 | 1.150 |
Why?
|
| Marijuana Abuse | 9 | 2017 | 411 | 1.100 |
Why?
|
| Isoflavones | 5 | 2015 | 136 | 1.070 |
Why?
|
| Alcohol Drinking | 13 | 2015 | 4028 | 1.070 |
Why?
|
| Plant Extracts | 4 | 2015 | 497 | 1.040 |
Why?
|
| Pyridines | 6 | 2014 | 2875 | 0.880 |
Why?
|
| GABA-A Receptor Agonists | 2 | 2014 | 86 | 0.870 |
Why?
|
| gamma-Aminobutyric Acid | 5 | 2022 | 1141 | 0.860 |
Why?
|
| Impulsive Behavior | 2 | 2018 | 346 | 0.860 |
Why?
|
| Smoking | 13 | 2023 | 9053 | 0.850 |
Why?
|
| Glutamic Acid | 6 | 2023 | 1176 | 0.850 |
Why?
|
| Sleep Deprivation | 5 | 2014 | 846 | 0.830 |
Why?
|
| Alcoholic Intoxication | 8 | 2011 | 174 | 0.820 |
Why?
|
| Central Nervous System Depressants | 4 | 2011 | 164 | 0.810 |
Why?
|
| Substance-Related Disorders | 28 | 2019 | 4420 | 0.810 |
Why?
|
| Methadone | 10 | 2012 | 321 | 0.780 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 4 | 2022 | 1081 | 0.750 |
Why?
|
| Nootropic Agents | 4 | 2011 | 157 | 0.750 |
Why?
|
| Affect | 17 | 2015 | 1486 | 0.690 |
Why?
|
| Attention | 8 | 2018 | 2396 | 0.680 |
Why?
|
| Sleep | 10 | 2014 | 4768 | 0.670 |
Why?
|
| Alcohol Deterrents | 2 | 2012 | 49 | 0.660 |
Why?
|
| Brain | 27 | 2023 | 27121 | 0.650 |
Why?
|
| Skin Temperature | 8 | 2008 | 96 | 0.620 |
Why?
|
| Narcotics | 6 | 2012 | 336 | 0.620 |
Why?
|
| Buprenorphine | 23 | 2009 | 656 | 0.610 |
Why?
|
| Heart Rate | 22 | 2016 | 4195 | 0.600 |
Why?
|
| Magnetic Resonance Imaging | 37 | 2023 | 36426 | 0.600 |
Why?
|
| Event-Related Potentials, P300 | 2 | 2018 | 149 | 0.590 |
Why?
|
| Naltrexone | 5 | 2013 | 317 | 0.590 |
Why?
|
| Magnetic Resonance Spectroscopy | 19 | 2016 | 3769 | 0.580 |
Why?
|
| Euphoria | 12 | 2006 | 65 | 0.580 |
Why?
|
| Double-Blind Method | 30 | 2015 | 12341 | 0.570 |
Why?
|
| Brain Mapping | 12 | 2019 | 6635 | 0.560 |
Why?
|
| Smoke | 2 | 2017 | 235 | 0.550 |
Why?
|
| Cerebral Cortex | 9 | 2019 | 5779 | 0.540 |
Why?
|
| Photic Stimulation | 11 | 2015 | 1987 | 0.510 |
Why?
|
| Adult | 132 | 2022 | 221210 | 0.510 |
Why?
|
| Psychomotor Performance | 10 | 2013 | 1882 | 0.500 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 5 | 2007 | 65 | 0.490 |
Why?
|
| Narcotic Antagonists | 6 | 2013 | 585 | 0.490 |
Why?
|
| Luteal Phase | 3 | 2015 | 138 | 0.460 |
Why?
|
| Energy Metabolism | 7 | 2014 | 2882 | 0.440 |
Why?
|
| Electroencephalography | 24 | 2018 | 6237 | 0.430 |
Why?
|
| Male | 146 | 2021 | 360846 | 0.420 |
Why?
|
| Hydrocortisone | 7 | 2023 | 1819 | 0.420 |
Why?
|
| Drug-Seeking Behavior | 1 | 2012 | 46 | 0.410 |
Why?
|
| Analysis of Variance | 15 | 2018 | 6228 | 0.380 |
Why?
|
| Reaction Time | 11 | 2018 | 2089 | 0.380 |
Why?
|
| Corpus Striatum | 3 | 2023 | 1235 | 0.370 |
Why?
|
| Executive Function | 3 | 2018 | 1392 | 0.370 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2022 | 144 | 0.370 |
Why?
|
| Neural Pathways | 3 | 2019 | 3060 | 0.370 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2001 | 297 | 0.370 |
Why?
|
| Anabolic Agents | 4 | 1999 | 256 | 0.350 |
Why?
|
| Body Temperature | 2 | 2006 | 781 | 0.350 |
Why?
|
| Self Administration | 26 | 2009 | 390 | 0.350 |
Why?
|
| Central Nervous System Stimulants | 4 | 2014 | 1177 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 36 | 2015 | 10766 | 0.340 |
Why?
|
| Humans | 171 | 2023 | 761596 | 0.340 |
Why?
|
| Prefrontal Cortex | 5 | 2022 | 2220 | 0.340 |
Why?
|
| Young Adult | 25 | 2019 | 59260 | 0.330 |
Why?
|
| Female | 114 | 2019 | 392705 | 0.330 |
Why?
|
| Visual Cortex | 4 | 2011 | 1108 | 0.320 |
Why?
|
| Evoked Potentials | 2 | 2015 | 1047 | 0.320 |
Why?
|
| Reality Therapy | 1 | 2008 | 5 | 0.320 |
Why?
|
| Phosphorus | 2 | 2007 | 335 | 0.320 |
Why?
|
| Oxygen | 7 | 2015 | 4227 | 0.310 |
Why?
|
| Rest | 1 | 2013 | 918 | 0.300 |
Why?
|
| Opiate Substitution Treatment | 1 | 2012 | 444 | 0.290 |
Why?
|
| Morphinans | 6 | 1988 | 27 | 0.290 |
Why?
|
| Aggression | 4 | 2000 | 750 | 0.280 |
Why?
|
| Benztropine | 1 | 2006 | 17 | 0.280 |
Why?
|
| Cross-Over Studies | 7 | 2012 | 2079 | 0.280 |
Why?
|
| Reward | 4 | 2022 | 971 | 0.270 |
Why?
|
| Cognition | 7 | 2022 | 6992 | 0.270 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2012 | 1241 | 0.270 |
Why?
|
| Protons | 3 | 2022 | 1116 | 0.260 |
Why?
|
| Muscarinic Antagonists | 1 | 2006 | 135 | 0.260 |
Why?
|
| Alpha Rhythm | 4 | 2008 | 111 | 0.260 |
Why?
|
| Depressive Disorder | 5 | 2015 | 3728 | 0.260 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 960 | 0.250 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2006 | 1541 | 0.240 |
Why?
|
| Opioid-Related Disorders | 9 | 2012 | 2164 | 0.240 |
Why?
|
| Blood Pressure | 12 | 2009 | 8481 | 0.240 |
Why?
|
| Administration, Cutaneous | 5 | 2013 | 713 | 0.230 |
Why?
|
| Prolactin | 3 | 2005 | 625 | 0.230 |
Why?
|
| Behavior | 6 | 2003 | 541 | 0.230 |
Why?
|
| Arousal | 6 | 2018 | 1166 | 0.230 |
Why?
|
| Smell | 1 | 2006 | 259 | 0.230 |
Why?
|
| Conditioning, Operant | 9 | 1993 | 310 | 0.220 |
Why?
|
| Eating | 8 | 2006 | 1539 | 0.220 |
Why?
|
| Age of Onset | 3 | 2018 | 3306 | 0.220 |
Why?
|
| Growth Hormone | 1 | 2005 | 569 | 0.210 |
Why?
|
| Morphine | 7 | 1994 | 657 | 0.210 |
Why?
|
| Nalbuphine | 3 | 1999 | 20 | 0.210 |
Why?
|
| Dopamine Agonists | 1 | 2005 | 352 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 11 | 2015 | 6019 | 0.200 |
Why?
|
| Schizophrenia | 6 | 2016 | 6937 | 0.200 |
Why?
|
| Vasodilator Agents | 1 | 2006 | 973 | 0.200 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2002 | 190 | 0.190 |
Why?
|
| Dopamine | 4 | 2023 | 1607 | 0.190 |
Why?
|
| Homeostasis | 3 | 2014 | 3323 | 0.190 |
Why?
|
| Plant Roots | 2 | 2011 | 117 | 0.180 |
Why?
|
| Nitrates | 1 | 2022 | 263 | 0.180 |
Why?
|
| Beer | 2 | 2015 | 134 | 0.180 |
Why?
|
| Mecamylamine | 1 | 2000 | 27 | 0.180 |
Why?
|
| Menstrual Cycle | 3 | 2002 | 539 | 0.180 |
Why?
|
| Nerve Net | 1 | 2013 | 2291 | 0.180 |
Why?
|
| Alveolar Process | 1 | 2021 | 294 | 0.180 |
Why?
|
| Antipsychotic Agents | 4 | 2008 | 3067 | 0.170 |
Why?
|
| Nicotinic Antagonists | 1 | 2000 | 94 | 0.170 |
Why?
|
| Glutamine | 2 | 2021 | 577 | 0.170 |
Why?
|
| Motivation | 6 | 2008 | 2006 | 0.170 |
Why?
|
| Papio | 17 | 1986 | 669 | 0.170 |
Why?
|
| Single-Blind Method | 5 | 2014 | 1574 | 0.170 |
Why?
|
| Pentobarbital | 4 | 2008 | 153 | 0.170 |
Why?
|
| Nicotinic Agonists | 1 | 2001 | 265 | 0.160 |
Why?
|
| Evoked Potentials, Auditory | 4 | 1990 | 530 | 0.160 |
Why?
|
| Acculturation | 1 | 2000 | 178 | 0.160 |
Why?
|
| Brain Chemistry | 6 | 2014 | 960 | 0.160 |
Why?
|
| Body Temperature Regulation | 2 | 1999 | 292 | 0.160 |
Why?
|
| Behavior, Addictive | 3 | 2012 | 462 | 0.160 |
Why?
|
| Macaca mulatta | 19 | 1995 | 2329 | 0.150 |
Why?
|
| Follicular Phase | 2 | 2015 | 143 | 0.150 |
Why?
|
| Bone Remodeling | 1 | 2021 | 581 | 0.150 |
Why?
|
| Osteoclasts | 1 | 2021 | 711 | 0.150 |
Why?
|
| Ecosystem | 1 | 2022 | 490 | 0.150 |
Why?
|
| Psychotherapy, Group | 2 | 2012 | 413 | 0.150 |
Why?
|
| Sleep, REM | 3 | 1999 | 595 | 0.150 |
Why?
|
| Methadyl Acetate | 3 | 1982 | 7 | 0.140 |
Why?
|
| Pilot Projects | 10 | 2017 | 8633 | 0.140 |
Why?
|
| Time Factors | 20 | 2017 | 39969 | 0.140 |
Why?
|
| Decision Making | 1 | 2011 | 3929 | 0.140 |
Why?
|
| Placebos | 3 | 2011 | 1667 | 0.140 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2015 | 618 | 0.140 |
Why?
|
| Drug Synergism | 4 | 2005 | 1757 | 0.130 |
Why?
|
| Depressive Disorder, Major | 1 | 2014 | 4762 | 0.130 |
Why?
|
| Heroin | 5 | 1995 | 119 | 0.130 |
Why?
|
| Administration, Inhalation | 2 | 2017 | 1157 | 0.130 |
Why?
|
| Electrocardiography | 7 | 2009 | 6377 | 0.130 |
Why?
|
| Age Factors | 6 | 2019 | 18399 | 0.130 |
Why?
|
| Phencyclidine | 3 | 1985 | 60 | 0.130 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2016 | 141 | 0.120 |
Why?
|
| Diterpenes, Clerodane | 1 | 2015 | 42 | 0.120 |
Why?
|
| Morphine Dependence | 1 | 1994 | 27 | 0.120 |
Why?
|
| Diazepam | 4 | 1985 | 215 | 0.120 |
Why?
|
| Drug Interactions | 5 | 2002 | 1416 | 0.120 |
Why?
|
| Postural Balance | 2 | 1989 | 622 | 0.110 |
Why?
|
| Gender Identity | 1 | 2000 | 766 | 0.110 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2015 | 138 | 0.110 |
Why?
|
| Dehydroepiandrosterone | 1 | 2015 | 258 | 0.110 |
Why?
|
| Cardiovascular System | 1 | 2001 | 834 | 0.110 |
Why?
|
| Family Health | 2 | 2010 | 1257 | 0.110 |
Why?
|
| Creatine Kinase | 2 | 2014 | 685 | 0.110 |
Why?
|
| Reference Values | 3 | 2011 | 4920 | 0.110 |
Why?
|
| Dextroamphetamine | 4 | 2008 | 134 | 0.110 |
Why?
|
| Fluorescence Polarization | 1 | 2013 | 140 | 0.110 |
Why?
|
| Middle Aged | 27 | 2017 | 220921 | 0.110 |
Why?
|
| Substance Abuse Detection | 3 | 2011 | 301 | 0.110 |
Why?
|
| ATP Synthetase Complexes | 1 | 2012 | 5 | 0.110 |
Why?
|
| Neuropsychology | 1 | 1993 | 107 | 0.110 |
Why?
|
| Analgesics, Opioid | 4 | 2015 | 3808 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2021 | 8181 | 0.100 |
Why?
|
| Doping in Sports | 1 | 1993 | 62 | 0.100 |
Why?
|
| Animals | 49 | 2022 | 168475 | 0.100 |
Why?
|
| NAD | 1 | 2016 | 614 | 0.100 |
Why?
|
| Central Nervous System | 2 | 1999 | 1336 | 0.100 |
Why?
|
| Infusions, Intravenous | 3 | 2006 | 2217 | 0.100 |
Why?
|
| Neuropsychological Tests | 4 | 2015 | 7054 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2022 | 1226 | 0.100 |
Why?
|
| Electrooculography | 2 | 2009 | 113 | 0.100 |
Why?
|
| Phosphates | 1 | 2015 | 770 | 0.100 |
Why?
|
| Anxiety | 1 | 2006 | 4573 | 0.100 |
Why?
|
| Fluoxetine | 2 | 1996 | 733 | 0.100 |
Why?
|
| Linear Models | 3 | 2012 | 5872 | 0.090 |
Why?
|
| Wechsler Scales | 1 | 2011 | 257 | 0.090 |
Why?
|
| Mood Disorders | 1 | 2018 | 1127 | 0.090 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2016 | 575 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2015 | 9001 | 0.090 |
Why?
|
| Naloxone | 2 | 2009 | 370 | 0.090 |
Why?
|
| Smoking Cessation | 2 | 2013 | 2057 | 0.090 |
Why?
|
| Cognition Disorders | 3 | 2012 | 3980 | 0.090 |
Why?
|
| Cerebellum | 2 | 2010 | 1501 | 0.090 |
Why?
|
| Sensory Thresholds | 6 | 2000 | 377 | 0.090 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1991 | 99 | 0.090 |
Why?
|
| Coronary Circulation | 1 | 2016 | 1569 | 0.090 |
Why?
|
| Medication Adherence | 2 | 2012 | 2176 | 0.090 |
Why?
|
| Rats | 7 | 2021 | 23741 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2022 | 1958 | 0.090 |
Why?
|
| Polysomnography | 4 | 2013 | 1848 | 0.090 |
Why?
|
| Administration, Oral | 4 | 2009 | 4021 | 0.090 |
Why?
|
| Chlorpromazine | 2 | 2008 | 111 | 0.090 |
Why?
|
| Sleep Stages | 3 | 2012 | 694 | 0.090 |
Why?
|
| Drug Tolerance | 3 | 1992 | 367 | 0.080 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2009 | 80 | 0.080 |
Why?
|
| Behavior, Animal | 6 | 1994 | 1878 | 0.080 |
Why?
|
| Frontal Lobe | 2 | 2014 | 1420 | 0.080 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 962 | 0.080 |
Why?
|
| Auditory Threshold | 4 | 1985 | 369 | 0.080 |
Why?
|
| Adolescent | 16 | 2022 | 88326 | 0.080 |
Why?
|
| Receptors, Opioid | 2 | 2008 | 145 | 0.080 |
Why?
|
| Psychotropic Drugs | 1 | 1994 | 888 | 0.080 |
Why?
|
| Aversive Therapy | 1 | 2008 | 5 | 0.080 |
Why?
|
| Diprenorphine | 1 | 1988 | 13 | 0.080 |
Why?
|
| Acupuncture Points | 1 | 2009 | 111 | 0.080 |
Why?
|
| Affective Symptoms | 1 | 2012 | 417 | 0.080 |
Why?
|
| Recurrence | 3 | 2023 | 8466 | 0.080 |
Why?
|
| Chromatography, Gas | 1 | 2008 | 151 | 0.080 |
Why?
|
| Corpus Callosum | 1 | 2013 | 751 | 0.080 |
Why?
|
| Restless Legs Syndrome | 1 | 1991 | 233 | 0.080 |
Why?
|
| Phosphorus Isotopes | 3 | 2014 | 124 | 0.080 |
Why?
|
| Phospholipids | 2 | 2010 | 786 | 0.080 |
Why?
|
| Vasoconstriction | 3 | 2001 | 592 | 0.080 |
Why?
|
| Bipolar Disorder | 3 | 2016 | 5092 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 8527 | 0.080 |
Why?
|
| Electroacupuncture | 1 | 2008 | 66 | 0.070 |
Why?
|
| Drug Administration Schedule | 5 | 2009 | 4853 | 0.070 |
Why?
|
| Butorphanol | 3 | 1994 | 10 | 0.070 |
Why?
|
| Emotions | 5 | 2008 | 2739 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 3415 | 0.070 |
Why?
|
| Amphetamine | 1 | 1989 | 224 | 0.070 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2019 | 2400 | 0.070 |
Why?
|
| Indicators and Reagents | 1 | 2008 | 462 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 20100 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2008 | 2691 | 0.070 |
Why?
|
| Aging | 3 | 2010 | 8710 | 0.070 |
Why?
|
| Serum | 1 | 2008 | 209 | 0.070 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2009 | 170 | 0.070 |
Why?
|
| Memory, Short-Term | 1 | 2013 | 982 | 0.070 |
Why?
|
| Child Behavior Disorders | 1 | 2012 | 804 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2013 | 2257 | 0.070 |
Why?
|
| Receptors, GABA-A | 1 | 2011 | 623 | 0.070 |
Why?
|
| Computer Graphics | 1 | 2008 | 340 | 0.070 |
Why?
|
| Triazolam | 2 | 1985 | 16 | 0.070 |
Why?
|
| Putamen | 2 | 2004 | 292 | 0.070 |
Why?
|
| Combat Disorders | 1 | 2008 | 301 | 0.060 |
Why?
|
| Pupil | 1 | 2006 | 146 | 0.060 |
Why?
|
| Benzodiazepines | 5 | 2006 | 1132 | 0.060 |
Why?
|
| Occipital Lobe | 1 | 2007 | 374 | 0.060 |
Why?
|
| Beauty | 1 | 2005 | 41 | 0.060 |
Why?
|
| Androgens | 1 | 1993 | 1286 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2016 | 3113 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2016 | 3096 | 0.060 |
Why?
|
| Choice Behavior | 1 | 2011 | 825 | 0.060 |
Why?
|
| Plasma | 1 | 2008 | 586 | 0.060 |
Why?
|
| Neurobiology | 1 | 2006 | 137 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2019 | 5079 | 0.060 |
Why?
|
| Thalamus | 2 | 2009 | 1047 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2016 | 4471 | 0.060 |
Why?
|
| Noise | 1 | 2007 | 290 | 0.060 |
Why?
|
| Progesterone | 1 | 2009 | 742 | 0.060 |
Why?
|
| Case-Control Studies | 4 | 2014 | 22176 | 0.060 |
Why?
|
| Appetitive Behavior | 3 | 1995 | 39 | 0.060 |
Why?
|
| Electrodes | 1 | 2006 | 614 | 0.060 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 15843 | 0.060 |
Why?
|
| Vision, Ocular | 2 | 1985 | 455 | 0.060 |
Why?
|
| Culture | 1 | 2008 | 623 | 0.060 |
Why?
|
| Antimetabolites | 1 | 2004 | 129 | 0.060 |
Why?
|
| Basal Ganglia | 3 | 2004 | 554 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2008 | 702 | 0.060 |
Why?
|
| Phosphocreatine | 2 | 2014 | 261 | 0.060 |
Why?
|
| Task Performance and Analysis | 3 | 2004 | 763 | 0.060 |
Why?
|
| Deoxyglucose | 1 | 2004 | 333 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2008 | 644 | 0.050 |
Why?
|
| Reinforcement Schedule | 4 | 1995 | 123 | 0.050 |
Why?
|
| Infusions, Parenteral | 2 | 1982 | 397 | 0.050 |
Why?
|
| Catecholamines | 1 | 2004 | 386 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 957 | 0.050 |
Why?
|
| Autistic Disorder | 1 | 2012 | 1220 | 0.050 |
Why?
|
| Biotransformation | 1 | 2002 | 166 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2006 | 1988 | 0.050 |
Why?
|
| Ketamine | 2 | 1985 | 519 | 0.050 |
Why?
|
| Crops, Agricultural | 1 | 2022 | 35 | 0.050 |
Why?
|
| Clozapine | 1 | 2006 | 504 | 0.050 |
Why?
|
| Mental Recall | 2 | 2004 | 1221 | 0.050 |
Why?
|
| Intubation, Gastrointestinal | 2 | 1983 | 166 | 0.050 |
Why?
|
| Environment | 1 | 2008 | 1123 | 0.050 |
Why?
|
| Nitrogen Oxides | 1 | 2022 | 129 | 0.050 |
Why?
|
| Vasopressins | 1 | 2003 | 351 | 0.050 |
Why?
|
| Serotonin | 2 | 2003 | 1041 | 0.050 |
Why?
|
| Psychometrics | 1 | 2011 | 3065 | 0.050 |
Why?
|
| Heroin Dependence | 3 | 1996 | 172 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2013 | 2791 | 0.050 |
Why?
|
| Aspartic Acid | 4 | 2009 | 576 | 0.050 |
Why?
|
| Equipment Design | 2 | 2009 | 3511 | 0.050 |
Why?
|
| Soil | 1 | 2022 | 115 | 0.050 |
Why?
|
| Pentazocine | 3 | 1986 | 12 | 0.050 |
Why?
|
| Salivation | 1 | 2001 | 22 | 0.050 |
Why?
|
| Demography | 1 | 2006 | 1648 | 0.050 |
Why?
|
| Catheters, Indwelling | 2 | 1983 | 426 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2005 | 1880 | 0.050 |
Why?
|
| Restraint, Physical | 1 | 1982 | 187 | 0.050 |
Why?
|
| Agriculture | 1 | 2022 | 190 | 0.050 |
Why?
|
| Clathrin | 1 | 2022 | 257 | 0.050 |
Why?
|
| Motor Activity | 1 | 2011 | 2715 | 0.050 |
Why?
|
| Injections, Intravenous | 6 | 2003 | 1379 | 0.040 |
Why?
|
| Blood Volume | 2 | 2001 | 547 | 0.040 |
Why?
|
| Psychotic Disorders | 1 | 2015 | 3223 | 0.040 |
Why?
|
| Methylphenidate | 1 | 2004 | 488 | 0.040 |
Why?
|
| Stress, Physiological | 2 | 2003 | 1403 | 0.040 |
Why?
|
| Self Concept | 1 | 1986 | 1045 | 0.040 |
Why?
|
| Color Perception | 1 | 2000 | 213 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2000 | 325 | 0.040 |
Why?
|
| Social Identification | 1 | 2000 | 108 | 0.040 |
Why?
|
| Visual Perception | 1 | 2008 | 1389 | 0.040 |
Why?
|
| Prevalence | 2 | 2006 | 15733 | 0.040 |
Why?
|
| Face | 1 | 2005 | 1026 | 0.040 |
Why?
|
| Polycythemia | 1 | 1999 | 124 | 0.040 |
Why?
|
| Time | 2 | 2015 | 546 | 0.040 |
Why?
|
| Crack Cocaine | 1 | 1998 | 32 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2022 | 602 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 3206 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 2 | 1998 | 2727 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2014 | 26129 | 0.040 |
Why?
|
| Stress, Psychological | 2 | 2003 | 4481 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 4 | 1984 | 397 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 1989 | 1496 | 0.040 |
Why?
|
| Hemodynamics | 3 | 2002 | 4160 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2014 | 2496 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 6403 | 0.030 |
Why?
|
| Inpatients | 1 | 2008 | 2548 | 0.030 |
Why?
|
| Sex Factors | 4 | 2001 | 10554 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2000 | 635 | 0.030 |
Why?
|
| Blood Cells | 1 | 1998 | 305 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2003 | 1199 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 1996 | 288 | 0.030 |
Why?
|
| Water | 1 | 2022 | 1411 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 1999 | 673 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2022 | 1475 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2022 | 863 | 0.030 |
Why?
|
| HIV Infections | 1 | 2022 | 17354 | 0.030 |
Why?
|
| Receptors, Opioid, delta | 1 | 1995 | 48 | 0.030 |
Why?
|
| Vision Tests | 1 | 2015 | 161 | 0.030 |
Why?
|
| Psychophysics | 1 | 2015 | 292 | 0.030 |
Why?
|
| Imipramine | 1 | 1994 | 98 | 0.030 |
Why?
|
| Butyrylcholinesterase | 1 | 1994 | 21 | 0.030 |
Why?
|
| Cholinesterases | 1 | 1994 | 32 | 0.030 |
Why?
|
| Health Status | 3 | 2009 | 4077 | 0.030 |
Why?
|
| Organ Size | 1 | 2019 | 2254 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 1996 | 477 | 0.030 |
Why?
|
| Macaca nemestrina | 3 | 1988 | 21 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2016 | 5247 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 2015 | 561 | 0.030 |
Why?
|
| Risk Factors | 5 | 2011 | 74213 | 0.030 |
Why?
|
| Veterans | 1 | 2008 | 2649 | 0.030 |
Why?
|
| Psychomotor Agitation | 1 | 1996 | 305 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2015 | 1141 | 0.030 |
Why?
|
| Circadian Rhythm | 3 | 2003 | 2576 | 0.030 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 1992 | 1148 | 0.030 |
Why?
|
| Pyrrolidines | 1 | 2015 | 338 | 0.030 |
Why?
|
| Haloperidol | 1 | 1994 | 389 | 0.030 |
Why?
|
| Barbiturates | 3 | 1983 | 113 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2008 | 4812 | 0.030 |
Why?
|
| Learning | 1 | 2022 | 1740 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 1994 | 903 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2009 | 6345 | 0.030 |
Why?
|
| Aged | 9 | 2016 | 169310 | 0.030 |
Why?
|
| Sports | 1 | 1999 | 705 | 0.030 |
Why?
|
| Wakefulness | 1 | 1999 | 1265 | 0.030 |
Why?
|
| Spleen | 1 | 1998 | 2295 | 0.030 |
Why?
|
| Cotinine | 1 | 2013 | 206 | 0.030 |
Why?
|
| Testosterone | 3 | 1995 | 2472 | 0.030 |
Why?
|
| Nucleotides | 1 | 2014 | 454 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 361 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2017 | 879 | 0.020 |
Why?
|
| Memory | 2 | 2013 | 2193 | 0.020 |
Why?
|
| Comorbidity | 1 | 2006 | 10508 | 0.020 |
Why?
|
| Quality Control | 1 | 1994 | 832 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2014 | 64685 | 0.020 |
Why?
|
| Caudate Nucleus | 2 | 2004 | 390 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1998 | 1474 | 0.020 |
Why?
|
| Desipramine | 1 | 1990 | 182 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2231 | 0.020 |
Why?
|
| Suicide, Attempted | 1 | 1999 | 1402 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2013 | 547 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2004 | 6391 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 1222 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1996 | 1440 | 0.020 |
Why?
|
| Hippocampus | 1 | 2022 | 3766 | 0.020 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 6484 | 0.020 |
Why?
|
| Discrimination Learning | 2 | 1995 | 278 | 0.020 |
Why?
|
| Microcomputers | 1 | 1989 | 141 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 1992 | 552 | 0.020 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1996 | 975 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2264 | 0.020 |
Why?
|
| Regional Blood Flow | 2 | 2004 | 1496 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 15266 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2009 | 353 | 0.020 |
Why?
|
| Piperazines | 2 | 2015 | 2523 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1992 | 702 | 0.020 |
Why?
|
| Methamphetamine | 1 | 2009 | 165 | 0.020 |
Why?
|
| Hematocrit | 2 | 1999 | 623 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1992 | 701 | 0.020 |
Why?
|
| Computational Biology | 1 | 2019 | 3517 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 1989 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 4575 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 1989 | 641 | 0.020 |
Why?
|
| Electromyography | 2 | 1996 | 1394 | 0.020 |
Why?
|
| Boston | 1 | 2000 | 9327 | 0.020 |
Why?
|
| Amphetamines | 1 | 2007 | 143 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 3597 | 0.020 |
Why?
|
| Inositol | 1 | 2007 | 215 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2006 | 119 | 0.020 |
Why?
|
| Catheterization | 2 | 1982 | 1428 | 0.020 |
Why?
|
| Choline | 2 | 2000 | 515 | 0.020 |
Why?
|
| Cyclazocine | 1 | 1985 | 10 | 0.020 |
Why?
|
| Thrombosis | 1 | 1999 | 2942 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2006 | 458 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 2650 | 0.020 |
Why?
|
| Autoradiography | 1 | 2006 | 728 | 0.020 |
Why?
|
| Electrophysiology | 1 | 1988 | 1262 | 0.010 |
Why?
|
| Education | 1 | 2008 | 537 | 0.010 |
Why?
|
| Tripelennamine | 1 | 1984 | 6 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1999 | 9319 | 0.010 |
Why?
|
| Benzodiazepinones | 1 | 1984 | 50 | 0.010 |
Why?
|
| Flumazenil | 1 | 1984 | 84 | 0.010 |
Why?
|
| Gambling | 1 | 2008 | 258 | 0.010 |
Why?
|
| Homovanillic Acid | 1 | 2003 | 75 | 0.010 |
Why?
|
| Nucleoside-Triphosphatase | 1 | 2003 | 19 | 0.010 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2003 | 93 | 0.010 |
Why?
|
| Glycerylphosphorylcholine | 1 | 2003 | 25 | 0.010 |
Why?
|
| Feeding Behavior | 2 | 1993 | 3188 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 12059 | 0.010 |
Why?
|
| Public Policy | 1 | 2007 | 559 | 0.010 |
Why?
|
| Dominance, Cerebral | 1 | 2004 | 623 | 0.010 |
Why?
|
| Codeine | 1 | 1983 | 51 | 0.010 |
Why?
|
| Heterosexuality | 1 | 2005 | 309 | 0.010 |
Why?
|
| Hemoglobins | 2 | 1999 | 1526 | 0.010 |
Why?
|
| Gait | 1 | 1988 | 814 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13510 | 0.010 |
Why?
|
| Food | 3 | 1995 | 774 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2002 | 6845 | 0.010 |
Why?
|
| Family | 2 | 1990 | 3195 | 0.010 |
Why?
|
| Light | 1 | 2008 | 1353 | 0.010 |
Why?
|
| Clonidine | 1 | 1982 | 169 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2004 | 897 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 2004 | 518 | 0.010 |
Why?
|
| Child Abuse | 1 | 2010 | 1077 | 0.010 |
Why?
|
| Social Class | 1 | 2010 | 2004 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 14665 | 0.010 |
Why?
|
| Epinephrine | 1 | 2004 | 792 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1982 | 2088 | 0.010 |
Why?
|
| Neurons, Afferent | 1 | 1983 | 498 | 0.010 |
Why?
|
| Estradiol | 1 | 1988 | 1937 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1983 | 578 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2009 | 2526 | 0.010 |
Why?
|
| Heterocyclic Compounds | 1 | 2001 | 246 | 0.010 |
Why?
|
| Respiration | 1 | 1986 | 1656 | 0.010 |
Why?
|
| Dogs | 1 | 1985 | 3839 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1999 | 157 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 1999 | 124 | 0.010 |
Why?
|
| Poisson Distribution | 1 | 2000 | 504 | 0.010 |
Why?
|
| Veins | 1 | 1983 | 768 | 0.010 |
Why?
|
| Drug Combinations | 2 | 1995 | 2048 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2004 | 1173 | 0.010 |
Why?
|
| Motor Neurons | 1 | 1983 | 870 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 2001 | 647 | 0.010 |
Why?
|
| Patient Selection | 1 | 2009 | 4244 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2009 | 10090 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1993 | 8002 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 6965 | 0.010 |
Why?
|
| Gadolinium | 1 | 2001 | 960 | 0.010 |
Why?
|
| Baths | 1 | 1996 | 53 | 0.010 |
Why?
|
| Azocines | 1 | 1995 | 20 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1995 | 213 | 0.010 |
Why?
|
| Stomach | 1 | 1979 | 696 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 81539 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 2 | 1987 | 726 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1998 | 1122 | 0.010 |
Why?
|
| Hyperthyroidism | 1 | 1996 | 294 | 0.010 |
Why?
|
| Luteinizing Hormone | 2 | 1987 | 820 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1995 | 554 | 0.010 |
Why?
|
| Pain | 1 | 2009 | 5073 | 0.010 |
Why?
|
| Estrogens | 1 | 2000 | 1522 | 0.010 |
Why?
|
| Child | 2 | 2012 | 80158 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 14608 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1996 | 834 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 54423 | 0.010 |
Why?
|
| Eye Movements | 1 | 1996 | 511 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 1998 | 852 | 0.010 |
Why?
|
| Conditioning, Classical | 1 | 1995 | 368 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1998 | 1281 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1996 | 668 | 0.010 |
Why?
|
| Creatine | 1 | 1994 | 427 | 0.010 |
Why?
|
| Libido | 1 | 1992 | 119 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2005 | 39106 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1998 | 1432 | 0.010 |
Why?
|
| Massachusetts | 1 | 2003 | 8833 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1998 | 1695 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2000 | 2884 | 0.010 |
Why?
|
| Benzamides | 1 | 1995 | 1371 | 0.010 |
Why?
|
| Algorithms | 1 | 1990 | 14033 | 0.010 |
Why?
|
| Body Weight | 1 | 1979 | 4618 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1989 | 861 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1993 | 1334 | 0.000 |
Why?
|
| Contrast Media | 1 | 2001 | 5307 | 0.000 |
Why?
|
| Breath Tests | 1 | 1988 | 299 | 0.000 |
Why?
|
| Risk | 2 | 1990 | 9610 | 0.000 |
Why?
|
| Intelligence Tests | 1 | 1988 | 503 | 0.000 |
Why?
|
| Self-Assessment | 1 | 1988 | 397 | 0.000 |
Why?
|
| Endorphins | 1 | 1985 | 74 | 0.000 |
Why?
|
| Saimiri | 1 | 1986 | 334 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 58984 | 0.000 |
Why?
|
| Bromazepam | 1 | 1984 | 1 | 0.000 |
Why?
|
| Phencyclidine Abuse | 1 | 1984 | 8 | 0.000 |
Why?
|
| Generalization, Stimulus | 1 | 1984 | 13 | 0.000 |
Why?
|
| Avoidance Learning | 1 | 1986 | 248 | 0.000 |
Why?
|
| Alprazolam | 1 | 1984 | 102 | 0.000 |
Why?
|
| Research Design | 1 | 2000 | 6180 | 0.000 |
Why?
|
| Lorazepam | 1 | 1984 | 154 | 0.000 |
Why?
|
| Femoral Vein | 1 | 1982 | 153 | 0.000 |
Why?
|
| Perception | 1 | 1988 | 1197 | 0.000 |
Why?
|
| Acoustic Stimulation | 1 | 1985 | 1235 | 0.000 |
Why?
|
| Self Medication | 1 | 1981 | 117 | 0.000 |
Why?
|
| Caffeine | 1 | 1984 | 700 | 0.000 |
Why?
|
| Kinetics | 1 | 1987 | 6374 | 0.000 |
Why?
|
| Anesthetics | 1 | 1983 | 523 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1995 | 18255 | 0.000 |
Why?
|